Appointment of M/s Suresh Surana & Associates LLP as Internal Auditor of the Company for FY 2026-27.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported strong FY2025-26 audited results with standalone revenue of Rs 300.68 crore (up 20.7% YoY) and consolidated revenue of Rs 310.41 crore (up 23.1% YoY). Standalone profit after tax grew to Rs 34.06 crore with EPS of Rs 6.54. The Board recommended a dividend of Rs 0.50 per share (25% on face value Rs 2) for FY25-26, subject to shareholder approval at the 21st AGM on September 2, 2026. This is the first dividend recommendation since listing (FY24-25 was nil). The Board also approved appointment of M/s Suresh Surana & Associates LLP as Internal Auditor for FY2026-27 and reappointed M/s S Chhaparia & Associates as Cost Auditor. Statutory auditors MSKA & Associates issued an unmodified opinion on both standalone and consolidated financials. Key notes include completion of Fetomat Wellness acquisition (63% stake, April 2025) and a dispute with Government of Meghalaya with Rs 392.20 lakh exposure.
Positive for shareholders: strong revenue growth, maiden dividend post-listing, and clean audit opinion signal financial health. The internal auditor appointment is routine and does not indicate any governance concerns.